S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
How Much Longer Will It Be Under $1? (Ad)pixel
NASDAQ:EVLO

Evelo Biosciences - EVLO Stock Forecast, Price & News

$2.74
-0.15 (-5.19%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.72
$3.00
50-Day Range
$1.71
$3.01
52-Week Range
$1.42
$12.74
Volume
96,499 shs
Average Volume
302,068 shs
Market Capitalization
$147.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.63

Evelo Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
725.7% Upside
$22.63 Price Target
Short Interest
Bearish
7.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Evelo Biosciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Acquiring Shares
$40 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

453rd out of 1,117 stocks

Pharmaceutical Preparations Industry

221st out of 550 stocks

EVLO stock logo

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Evelo Biosciences Price Performance

Shares of Evelo Biosciences stock traded down $0.15 during mid-day trading on Friday, reaching $2.74. 96,700 shares of the stock traded hands, compared to its average volume of 302,068. The business has a 50-day moving average of $2.25 and a 200 day moving average of $2.79. Evelo Biosciences has a fifty-two week low of $1.42 and a fifty-two week high of $12.74. The stock has a market capitalization of $147.03 million, a PE ratio of -1.22 and a beta of 1.57. The company has a quick ratio of 2.67, a current ratio of 2.67 and a debt-to-equity ratio of 5.37.

Evelo Biosciences (NASDAQ:EVLO - Get Rating) last announced its earnings results on Thursday, August 11th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.16. During the same period last year, the firm posted ($0.59) EPS. On average, analysts predict that Evelo Biosciences will post -2.01 EPS for the current year.

Insider Buying and Selling

In other Evelo Biosciences news, major shareholder Ventures Fund Iv Gene Flagship acquired 27,397,259 shares of the stock in a transaction that occurred on Friday, May 27th. The stock was bought at an average cost of $1.46 per share, for a total transaction of $39,999,998.14. Following the completion of the transaction, the insider now owns 13,698,630 shares of the company's stock, valued at approximately $19,999,999.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

Earnings Preview For Evelo Biosciences
Evelo Biosciences Names Marella Thorell as CFO
Evelo Biosciences Appoints Marella Thorell As CFO
Evelo Jumps on Unveiling Direct Offering
Evelo Biosciences GAAP EPS of -$0.54 beats by $0.08
Evelo Biosciences's Earnings Outlook
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings
8/11/2022
Today
8/13/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.63
High Stock Price Forecast
$41.50
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+725.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-122,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.16 per share

Miscellaneous

Free Float
50,387,000
Market Cap
$147.03 million
Optionable
Not Optionable
Beta
1.57

Key Executives

  • Dr. Balkrishan Gill Ph.D. (Age 57)
    Pres, Interim Principal Financial Officer, CEO & Director
  • Dr. Jonathan B. Zung Ph.D. (Age 57)
    Chief Devel. Officer
    Comp: $713.28k
  • Mr. Stephen J. Carriere (Age 67)
    VP & Chief Accounting Officer
  • Dr. Chun Zhang Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Mark Bodmer (Age 64)
    Chief Scientific Officer and Pres of R&D
  • Ms. Kendra Sweeney
    Head of Investor Relations & Capital Markets
  • Mr. Daniel S. Char (Age 61)
    Gen. Counsel & Sec.
  • Ms. Jessica Cotrone
    VP & Head of Communications
  • Ms. Leslie Wardwell-Scott Ph.D.
    VP and Head of Corp. Devel. & Strategic Integration
  • Ms. Julie Carretero
    Chief People Officer













EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EVLO shares.
View EVLO analyst ratings
or view top-rated stocks.

What is Evelo Biosciences' stock price forecast for 2022?

4 equities research analysts have issued 1-year price targets for Evelo Biosciences' stock. Their EVLO share price forecasts range from $12.00 to $41.50. On average, they anticipate the company's stock price to reach $22.63 in the next year. This suggests a possible upside of 725.7% from the stock's current price.
View analysts price targets for EVLO
or view top-rated stocks among Wall Street analysts.

How have EVLO shares performed in 2022?

Evelo Biosciences' stock was trading at $6.07 at the beginning of 2022. Since then, EVLO stock has decreased by 54.9% and is now trading at $2.74.
View the best growth stocks for 2022 here
.

When is Evelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our EVLO earnings forecast
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings data on Thursday, August, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.16. During the same period in the previous year, the business posted ($0.59) EPS.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (30.16%), State of Michigan Retirement System (7.59%), abrdn plc (0.64%), Northern Trust Corp (0.13%), AE Wealth Management LLC (0.10%) and Group One Trading L.P. (0.00%). Insiders that own company stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends
.

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $2.74.

How much money does Evelo Biosciences make?

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $147.03 million. The company earns $-122,180,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Evelo Biosciences have?

The company employs 122 workers across the globe.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.